BioNote, Inc. (KRX:377740)

BioNote Income Statement

Financials in millions KRW. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Operating Revenue	105,917	102,780	90,081	479,657	622,355	631,505
Other Revenue	0	-	0	-0	-0	-
Revenue	105,917	102,780	90,081	479,657	622,355	631,505
Revenue Growth (YoY)	12.42%	14.10%	-81.22%	-22.93%	-1.45%	1476.89%
Cost of Revenue	52,389	51,807	101,739	139,186	110,352	51,950
Gross Profit	53,528	50,973	-11,659	340,471	512,003	579,554
Selling, General & Admin	23,533	22,868	22,787	31,519	24,340	13,102
Research & Development	14,008	13,577	13,405	16,138	11,300	7,612
Other Operating Expenses	244.9	265.78	168.12	176.92	345.29	45.46
Operating Expenses	40,058	38,756	35,510	45,062	43,255	21,523
Operating Income	13,470	12,218	-47,168	295,410	468,748	558,031
Interest Expense	-258.93	-233.55	-602.82	-84.44	-44.25	-172.63
Interest & Investment Income	18,227	20,059	24,630	9,715	873.63	37.56
Earnings From Equity Investments	20,144	18,910	-	-147,264	-	-
Currency Exchange Gain (Loss)	23,876	40,603	10,164	24,512	24,159	-5,726
Other Non Operating Income (Expenses)	1,069	1,096	420.84	-296.63	-123.11	-75.83
EBT Excluding Unusual Items	76,528	92,653	-12,556	181,992	493,612	552,094
Gain (Loss) on Sale of Investments	-15,700	-14,511	-88,791	219,374	376,239	143,115
Gain (Loss) on Sale of Assets	397.66	20.25	265.2	13,412	33.39	-11.45
Asset Writedown	-4,835	-4,835	-8,409	-	-	-
Pretax Income	56,391	73,327	-109,491	414,778	869,885	695,198
Income Tax Expense	14,014	18,065	-88,994	106,980	193,284	166,969
Net Income	42,377	55,261	-20,497	307,798	676,601	528,229
Net Income to Common	42,377	55,261	-20,497	307,798	676,601	528,229
Net Income Growth	121.02%	-	-	-54.51%	28.09%	2462.62%
Shares Outstanding (Basic)	102	102	102	94	94	94
Shares Outstanding (Diluted)	102	102	102	94	94	94
Shares Change (YoY)	-0.38%	-0.08%	8.16%	0.64%	0.14%	11.08%
EPS (Basic)	417.12	542.36	-200.99	3277.21	7232.04	5646.12
EPS (Diluted)	416.76	542.00	-201.00	3264.00	7222.00	5646.00
EPS Growth	121.94%	-	-	-54.81%	27.91%	2206.94%
Free Cash Flow	34,325	47,454	-8,156	206,834	485,966	213,228
Free Cash Flow Per Share	337.86	465.74	-79.98	2193.65	5186.94	2279.15
Gross Margin	50.54%	49.59%	-12.94%	70.98%	82.27%	91.77%
Operating Margin	12.72%	11.89%	-52.36%	61.59%	75.32%	88.37%
Profit Margin	40.01%	53.77%	-22.75%	64.17%	108.72%	83.65%
Free Cash Flow Margin	32.41%	46.17%	-9.05%	43.12%	78.09%	33.77%
EBITDA	21,753	20,404	-38,962	301,861	472,854	559,918
EBITDA Margin	20.54%	19.85%	-43.25%	62.93%	75.98%	88.66%
D&A For EBITDA	8,283	8,186	8,206	6,451	4,106	1,887
EBIT	13,470	12,218	-47,168	295,410	468,748	558,031
EBIT Margin	12.72%	11.89%	-52.36%	61.59%	75.32%	88.37%
Effective Tax Rate	24.85%	24.64%	-	25.79%	22.22%	24.02%
Advertising Expenses	-	2,422	2,414	2,332	1,063	540.13

Source: S&P Global Market Intelligence. Standard template. Financial Sources.